Media headlines about DBV Technologies (NASDAQ:DBVT) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DBV Technologies earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.7200828798905 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Several analysts have commented on DBVT shares. Zacks Investment Research raised shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Tuesday, August 29th. Morgan Stanley reaffirmed an “overweight” rating on shares of DBV Technologies in a research report on Monday, July 10th. Deutsche Bank AG started coverage on shares of DBV Technologies in a research report on Friday, June 23rd. They issued a “buy” rating and a $46.00 price objective on the stock. ValuEngine lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Friday, June 30th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of DBV Technologies in a research report on Thursday, July 6th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. DBV Technologies presently has an average rating of “Buy” and an average target price of $50.33.

DBV Technologies (NASDAQ:DBVT) traded down 0.05% during mid-day trading on Friday, hitting $43.41. 252,966 shares of the stock traded hands. DBV Technologies has a 1-year low of $31.87 and a 1-year high of $46.33. The stock’s market cap is $2.00 billion. The company’s 50 day moving average price is $44.06 and its 200-day moving average price is $37.85.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect DBV Technologies (DBVT) Stock Price” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/23/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-dbv-technologies-dbvt-stock-price.html.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Insider Buying and Selling by Quarter for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.